| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79ae6dd5bafbd2dd69035367385d754c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
| filingDate |
2019-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7c81abf028a1396052662cb1b9a689c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3df2f6b27863debeb1e12f18eadd47f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8d838adeb75f8302d1464001e07e54c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fb21ee00e225b9fe549ccfd89ed2757
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c848062b7696462e2b787aa2fe0e7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b82ebcc9106114606f2b11bc22d9f64b |
| publicationDate |
2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2732974-C1 |
| titleOfInvention |
Method for differential diagnosing of pancreatic diseases |
| abstract |
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, surgery, and can be used for differential diagnostics of pancreatic diseases. At the stage of examination in the blood of a patient with pancreatic disease by immunophenotyping, content of dehydroepiandrosterone-sulphate – DHEA-S and 17-oxyprogesterone – 17-OHP is determined. If the level of DHEA-S=2.4±0.2 and 17-OHP=0.42±0.40 patient is diagnosed with pancreatic neuroendocrine tumor. If DHEA-S=3.7±0.37 and 17-OHP=1.9±0.19 is diagnosed with pancreatic adenocarcinoma. If the level of DHEA-S=6.42±0.69 and 17-OHP=2.8±0.32 is diagnosed with chronic pancreatitis.EFFECT: method enables differential diagnostics of pancreatic diseases at the stages of primary examination by determining the content of DHEA-S and 17-oxyprogesterone – 17-OHP by immunophenotyping.1 cl, 1 tbl, 3 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2753601-C1 |
| priorityDate |
2019-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |